A recurrent de novo heterozygous COG4 variant leads to Saul-Wilson syndrome, disruption of vesicular trafficking, abnormal Golgi structure and altered glycosylation of a secreted proteoglycan
Introduction
Saul-Wilson syndrome (SWS) is a rare skeletal dysplasia with characteristic dysmorphic and radiographic findings, as well as early developmental delay, primarily involving speech, with eventual normal cognition. Clinical findings include marked short stature, prominent forehead with an enlarged anterior fontanel, prominent eyes with cataracts, narrow nasal bridge with a convex nasal ridge, micrognathia, clubfoot, brachydactyly, and short distal phalanges of fingers.
Radiographic changes include platyspondyly, irregular end plates of vertebral bodies, and hypoplasia of the odontoid process with cervical instability in the spine, coxa valga, overtubulation, metaphyseal flaring and megaepiphyses in the long bones, while the hands and feet exhibit short phalanges, metacarpals and metatarsals, cone-shaped epiphyses of phalanges, and accessory ossification centers of metacarpals and metatarsals. Since its original description in 1990 as a provisionally new skeletal dysplasia, only five cases have been reported, 1-3 all from different families. Some essential characteristics of SWS (i.e. severe preand postnatal growth retardation with possible microcephaly and skeletal dysplasia) can fall within the category of microcephalic osteodysplastic primordial dwarfism. 4, 5 In fact, a prior nosology of genetic skeletal disorders included SWS in the same group of slender bone dysplasias that contained microcephalic osteodysplastic primordial dwarfism type II (MOPDII, OMIM 210720). 6 However, due to the uncertainty about the etiology and identity of SWS as a genetic disorder, it was excluded from the two subsequent nosologies 7, 8 and, due to its rarity, it is not included as a discrete entity in the Online Mendelian Inheritance in Man (OMIM) catalog.
Here we present fourteen individuals with SWS and a recurrent de novo heterozygous variant in COG4 (MIM: 606976, NM_015386.2:c.1546G>A or c.1546G>C/p.Gly516Arg), a component of the Complex Oligomeric Golgi (COG) trafficking complex. The COG complex controls retrograde and anterograde vesicular protein trafficking and is composed of eight subunits distributed in two lobes, lobe A (COG1-4) and lobe B (COG5-8). 9 The COG complex interacts with various other proteins involved in vesicular trafficking, including SNARES, SNARE-interacting proteins, Rab GTPases, coiled-coil tethers, and COPI coat proteins. 10 Our description of the basic molecular defect in SWS expands the phenotypic spectrum of the disease and helps elucidate the cellular pathogenesis of this rare skeletal dysplasia. 
Materials and methods

Subjects
Genetic analysis
Different technologies and analysis pipelines were used for subjects sequenced by seven different institutions; details are presented in the Supplemental Methods section.
mRNA expression analysis
Total RNA was extracted from frozen fibroblast pellets using a Maxwell RSC instrument with the corresponding simplyRNA Cells Kit (Promega, Madison, WI, USA) following the manufacturers protocol with DNase1 treatment. Two g of RNA was reverse transcribed using the Omniscript Reverse Transcriptase kit (Qiagen, Valencia, CA, USA). Quantitative RT-PCR was performed on an Applied Biosystems 7500 Fast Real-Time PCR System (Life Technologies, Grand Island, NY, USA) using a TaqMan gene-expression mastermix and the following TaqMan assays: COG1 (Hs00372622_m1), COG2 (Hs00201197_m1), COG3 (Hs00230134_m1), COG4 (Hs01094456_m1), COG5 (Hs00197140_m1), COG6 (Hs01037401_m1), COG7 (Hs00411394_m1) and COG8 (Hs00260744_m1). Expression was normalized using GAPDH (Hs02758991_g1) and POLR2A (Hs00172187_m1) as endogenous controls.
Protein level analysis
For analysis of COG4, cells were harvested using SDS lysis buffer (62.5 mM Tris-HCl, pH 6.8, 2% SDS, and 10% glycerol) supplemented with protease and phosphatase inhibitors (Sigma-Aldrich, St. Louis, MO, USA). Lysates were sonicated, heated at 95°C for 5 min followed by centrifugation at 10,000 rpm for 5 min. Equivalent amounts of total lysates were then fractionated on a 4-15% polyacrylamide gel and transferred to a nitrocellulose membrane using the Transblot Turbo transfer system (Bio-Rad, Hercules, CA, USA). The membrane was blocked with Odyssey TBS Blocking buffer (LI-COR, Lincoln, NE, USA) and probed with anti-COG4 antibody produced in rabbit (A305-555A, Bethyl Laboratories, Montgomery, TX, USA) and anti-Vinculin antibody produced in mouse (V9131, Sigma Aldrich, St. Louis, MO, USA). Secondary antibodies Donkey anti-rabbit IRDye 680RD and Donkey anti-mouse IRDye 800CW (LI-COR, Lincoln, NE, USA) were applied and imaging was done using a 9140 Odyssey CLx infrared imaging system with Image Studio software for analysis (LI-COR, Lincoln, NE, USA).
For analysis of other COG subunits, human fibroblast cells were harvested by SDS lysis buffer as previously described. 14 
Protein modeling
The rope structure of three-dimensional protein homology models of wild-type and mutant (p.Gly516Arg) COG4 were built using the web interface of SWISS-MODEL with its default settings. 15, 16 Amino acid sequence of conserved oligomeric Golgi complex subunit 4 isoform 1 (NP_056201.2) in FASTA format was used as input. Template search was performed automatically by SWISS-MODEL using BLAST 17 and HHblits. 18 The template's quality was predicted from features of the target-template alignment, and the templates with the highest quality were selected for model building. The models were built based on the target-template alignment using ProMod3. The global and per-residue model quality was assessed using the QMEAN scoring function. 19 The modeled COG4 protein (aa range between 202-787) was superimposed onto the structural template 3HR0 (aa range between 540-789) to further evaluate the similarity of the modeled protein to the X-ray crystal of the C-terminal COG4 protein. 20 
Co-immunoprecipitation
Fibroblasts from control and three affected subjects were lysed in ice-cold Triton X-100 lysis buffer (50 mM Tris, pH 7.5, 150 mM sodium chloride, 1mM EDTA, 0.5% Triton X-100) supplemented with protease and phosphatase inhibitors (Sigma-Aldrich, St. Louis, MO, USA).
Cell lysates were centrifuged at 10,000 rpm (9,279g) for 10 min at 4°C to remove insoluble material. Subsequently, equivalent amounts of protein extracts were incubated with rabbit polyclonal anti-COG4 antibody (Bethyl Laboratories, Montgomery, TX, USA) for 2 h at 4°C and then with protein A beads overnight. After incubation, immunoprecipitates were washed three times with lysis buffer without protease or phosphatase inhibitors, eluted in SDS sample buffer and separated by SDS-PAGE. The different COG subunits were detected by immunoblotting using the indicated antibodies (Bethyl Laboratories, Montgomery, TX, USA). 
Golgi morphology by immunofluorescence
Golgi three-dimensional rendering and volumetric analysis
Alexa Fluor 488 anti-Giantin antibodies (BioLegend, San Diego, CA, USA) were used as a marker of the Golgi. All fibroblast Z-series reconstructions were imaged with a pinhole size of 1 Airy Unit and a Z-step interval of 0.2 µm at 4x magnification. LSM Z-series files of the Golgi were opened in Imaris software (Bitplane, South Windsor, CT, USA) as volumes, and the surface of the Golgi was smoothened by setting the surface detail at 0.1 µm. Each Golgi isosurface was visually inspected to ensure that it closely followed the underlying original three-dimensional image and did not incorporate voxels outside of the observable Golgi region. Each isosurfaced Golgi was selected and its volume recorded. 21 The nucleus was stained with DAPI (GeneTex Inc., Alton Pkwy, Irvine, CA) and its volume measured as above; the surface detail was set at 1 µm.
Decorin immunoblotting
For secreted decorin analysis, fibroblast cells were grown in normal condition for three days to reach ~80% confluency, then the media was replaced with serum-free medium. After 4 days, the medium was collected and concentrated using Microcon centrifugal filter unit YM-10 columns (MilliporeSigma, Darmstadt, Germany). For intracellular decorin analysis, cells were lysed in 0.1M Tris-Cl pH 8.0 buffer with protease inhibitor cocktail (Roche, Mannheim, Germany) followed by sonication. The concentrated media and cell lysate from fibroblast cultures were subjected to SDS-PAGE using 6 or 8% SDS polyacrylamide gels. Separated proteins were transferred to a PVDF membrane and decorin was detected with anti-human decorin antibody (clone 115402; R&D Systems, Minneapolis, MN, USA).
Brefeldin A-induced transport assays
For the brefeldin A (BFA)-induced retrograde transport assay, fibroblasts from two controls and four subjects were grown on glass cover slips for two days. After removal of the medium, cells were incubated with prewarmed normal growth medium containing 0.25 µg/ml BFA for 0, 7.5, 15, 22.5, 30 and 45 min at 23ᵒC. The incubations were stopped by washing cells with DPBS and cells were fixed with 4% paraformaldehyde for 10 min at room temperature. Cells were permeabilized and stained by immunofluorescence using Alexa Fluor 488 anti-Giantin antibodies (BioLegend, San Diego, CA, USA). The percentage of cells with ER staining was determined at the given time points. Images were obtained using an Olympus IX71 microscope For the anterograde transport assay, fibroblasts from two unaffected controls, four subjects and a positive control obtained from an individual with biallelic variants in COG8 22 were grown on glass cover slips for two days. After incubating the cells with 0.25 µg/ml brefeldin A for 1 h at 37ᵒC, cells were washed with DPBS twice, then switched to new plates with prewarmed normal growth medium and incubated for 0, 20, 30, 40, 60, 80, 100 and 120 min at 37ᵒC. The incubations were stopped and processed as described above.
COG complex subcellular fractionation
Fibroblasts from a control and an affected individual were gently collected by cell lifter, followed by cell disruption and differential centrifugation as previously described, 23 in order to assess the distribution of the COG subunits in their cytosolic and membrane-bound fractions.
Assessment of COG complex assembly by glycerol gradient centrifugation
Preparation of cytosolic and membrane-bound fractions for density centrifugation of one control and one subject fibroblast cell lines was performed as described 24 Trichloroacetic acid precipitation was performed followed by Western blot assays in order to measure the protein concentration of the samples.
Zebrafish maintenance and staging
Wild-type ABCxTu, cog4 b1311 , cog4 b1312 and transgenic Tg[p7.2sox10:mRFP] vu234 adult zebrafish 25 were maintained as previously described. 26 Embryos and larvae were staged according to the standard staging series. 27 All zebrafish procedures were approved by the University of Oregon Institutional Animal Care and Use Committee (IACUC).
Zebrafish immunolabeling, in situ hybridization, phalloidin staining and Alcian blue staining
Wholemount larvae were labeled following previously published protocols 28 Secondary antibodies were biotinylated horse anti-rabbit and biotinylated horse anti-mouse (Vector Laboratories, Burlingame, CA, USA; 1:500). The procedure for the in situ hybridization followed previously published protocols. 28 Larvae were hybridized with a digoxigenin-labeled RNA probe spanning a 736 bp coding sequence between exons 3 and 8 of cog4. Stained larvae were embedded in 1% agarose, 0.5% agar, 5% sucrose medium, and 16 µm cryosections were cut. Zebrafish RNA probe for collagen I alpha2 (col1a2) was kindly provided by Dr. John H.
Postlethwait. Phalloidin staining was performed as previously described. 29 Alcian blue staining was performed as previously described. 30 
Generation of indel mutant alleles using CRISPR
Two single guide RNAs (sgRNA) were designed that contained targeting sequences in exon 4 (5'-GGCTGTACCAAGCGATTCAG-3') and exon 12 (5'-GCTCTGCAGGACCTGCAGCG-3') of cog4, respectively. sgRNA and cas9 RNAs were co-injected at the 1-cell stage. Indel mutations were identified using the following primers: targeted sequence in exon 4: forward 5'-TGGCAGAAAATGTCAGCAGC-3' and reverse: 5'-GCAAAGGTAACCCTACTCGC-3'; targeted sequence in exon 12: forward: 5'-ACTCATAAGTTGCCAATCTAGT-3' and reverse: 5'-
Zebrafish imaging
Differential interference contrast images of the inner ear and images of Alcian blue stained ceratohyal cartilages were acquired using a Zeiss Axioplan2 compound microscope. Images of immunolabeled cells and larvae were acquired using a Zeiss LSM 5 confocal microscope. Images were analyzed using ImageJ (National Institutes of Health, Bethesda, MD, USA).
Statistical analysis
For Golgi morphology count, a Chi-squared test was performed using R 31 (script accessible in Supplemental Methods). For quantification of fibroblasts' glycan peak intensities, multiple ttests were performed (one per row), with correction for multiple comparisons performed via the Holm-Sidak method, alpha=5.0%, using Prism 6.0c (Graphpad Software Inc, La Jolla, CA, USA). For other statistical analyses, an unpaired Student's t-test was performed with Excel (Microsoft Corporation, Redmond, WA, USA). Statistical significance was assigned to a twotailed p-value <0.05.
Results
Clinical features
The clinical and imaging characteristics of fourteen individuals with SWS are summarized in Table 1 . Individuals P2.1 and P12.1 were previously reported as two of the original probands with SWS (P12.1 corresponds to subject 2 in the original description of the syndrome by Saul and Wilson 1 , whereas P2.1 corresponds to subject 1 in Hersh et al. 2 ). Affected newborns are born small for gestational age, have extreme short stature postnatally, and often have microcephaly, leading to a differential diagnosis within the microcephalic primordial dwarfism spectrum. Hearing loss appears to be another canonical feature of the disease. Representative clinical photos from subjects of different ages are shown in Figure 1 , whereas characteristic radiographic findings are shown in Figure S1 .
A recurrent heterozygous variant in COG4 causes Saul-Wilson syndrome
All subjects harbored one of two possible COG4 variants, c.1546G>A or c.1546G>C (GenBank: NM_015386.2). Both variants give rise to an identical de novo heterozygous amino acid substitution, p.Gly516Arg (NP_056201.2).
Compared to control cells, fibroblasts from affected individuals showed normal mRNA expression ( Figure 2A) , and protein level of COG4 ( Figure 2B ) and other COG subunits (not shown) was not decreased, confirming that the variant leads to production of a stable protein.
Protein modeling predicts the loss of a loop structure in the mutant protein ( Figure S2 ).
However, binding of COG4 to other COG subunits was not altered ( Figure S3 ).
Altered Golgi morphology and volume
Because the COG4 protein is part of a large COG complex that governs membrane movement between the Golgi and ER, we examined the morphology and total volume of the Golgi in fibroblasts obtained from individuals with SWS. Golgi morphology was significantly altered in fibroblasts of three tested subjects, with only 51.1% (n = 237, P1.1), 52.8% (n = 254, P4.1), and 54.9% (n = 268, P5.1) of the Golgi complexes exhibiting normal morphology in contrast to 93.9% (n = 214, GM01582) in control fibroblasts ( Figures 3A and 3B , Figure S4 ). Abnormal Golgi morphology was defined as co-localization of GM130 and TGN46, suggesting collapse of the cisand trans-Golgi stacks. The Golgi volume in affected subject cells was significantly decreased compared to that of unaffected cells (p < 0.0001), since the volume in controls averaged 491 μm3 based on staining with Giantin, a Golgi membrane marker; cells from affected individuals averaged 109 μm3 ( Figure 3C ). The nuclear volume was also decreased (1,158 μm3 in controls, 729 μm3 in cells from affected subjects, p = 0.0016). After normalizing to nuclear volume, the volume of the Golgi in cells from affected individuals was 2.8-fold lower compared to that in control cells (p = 0.0005).
Protein glycosylation occurs in the Golgi apparatus. Nevertheless, despite the marked reduction in Golgi volume within cells from subjects, glycan analysis in the mutant fibroblasts ( Figure S5) and serum/plasma ( Figure S6 ), as well as glycosylation status of serum transferrin and apoCIII (not shown), were not measurably different from that of controls.
The initiation and polymerization of glycosaminoglycans onto its core protein (i.e., the glycosylation of proteoglycans) also takes place mainly in the Golgi apparatus. More than 98% of decorin was secreted by fibroblasts to the extracellular matrix (data not shown). Extracellular decorin from affected individuals showed a greater proportion of higher molecular weight components compared to control cells ( Figure 4A) . Similarly, intracellular decorin in affected individuals exhibited a clear upward shift of the bands containing glycosaminoglycan (GAG) chains ( Figure 4B ). Finally, a smaller proportion of intracellular decorin contained extended GAG chains in affected individuals when compared to controls ( Figure 4C ).
Brefeldin A-induced protein transport is impaired
Brefeldin A (BFA) is an inhibitor of the vesicle membrane trafficking mediated by the coat protein complex, COPI. Such trafficking is involved in the process of Golgi-to-ER retrograde transport, 32, 33 in which the COG complex functions; hence BFA is widely used to examine the phenotype of human COG mutant cells. We treated control and affected subject fibroblasts with 0.25 µg/ml BFA at room temperature and recorded the increase in the ER-localized staining of Giantin over time. In previous studies using cells from individuals with biallelic variants in a single COG subunit, cells showed a delayed response to BFA treatment. 14, 22, 24, 34, 35 Surprisingly, the BFA-induced retrograde transport was significantly faster in affected subject cells compared to controls ( Figure 5A ). In contrast, when BFA was washed out and the Golgi allowed to reform, the anterograde transport was slower in cells from affected subjects compared to controls ( Figure 5B ).
The trans-Golgi network (TGN) is a tubular-reticular structure adjacent to the trans-Golgi cisternae, acting as a protein sorting station with a role both in protein secretion and endocytosis. 36 BFA is known to produce effects in Golgi cisternae different from those in the TGN. 37 In particular, BFA is known to alter the kinetics of recycling between the plasma membrane and the TGN. 38 After BFA treatment, TGN46 was distributed in the cytoplasm as small, membrane-bound structures. Although the rate of loss of TGN structure was difficult to objectively quantify, this TGN breakdown appeared slightly faster in affected cells than in control cells; this difference was seen mainly 30 min after treatment ( figure S7 ).
The subcellular localization of COG subunits is unaltered
Fractionation assays by differential centrifugation showed that the subcellular distribution of COG4 is unaltered. The majority of COG4 is in the cytosolic fraction (supernatant fraction from 100,000g spin or 100kgS) and less than 5% of COG4 is membrane-bound (large membrane pellet fraction from 15,000g spin or 15kgP, and small membrane pellet fraction from 100,000g spin or 100kgP) in control and subjects' cells ( Figure S8 ). This is consistent with published data on COG4 distribution. 24 The cytosolic vs membrane-bound distribution of the other COG subunits was also similar in control and affected subject cells ( Figure S8) .
A portion of COG4 assembles into larger complexes
The COG complex comprises eight subunits and their association and dissociation is dynamic.
Density gradient centrifugation is a sensitive method to separate different-sized complexes formed by COG subunits. 24 We observed the presence of two peaks of COG4 in the cytosolic fraction: the majority is present in fraction 4 in both control and subjects' cells ( Figure S9 ) but there was a visible shift of approximately 13% of COG4 to heavier fractions in affected subject cells. The result indicates that a greater portion of COG4 exists in larger complexes.
Zebrafish COG4 -/mutants have inner ear, growth and skeletal defects
To establish the normal developmental functions of COG4, we used CRISPR/Cas9 gene editing to generate two mutant alleles of the zebrafish ortholog, cog4 ( Figure S10 ). Both mutations introduced frameshifts followed by premature stop codons, one in exon 4 (cog4 b1311 , c.352_359del, p.I118Gfs*) and the other in exon 12 (cog4 b1312 , c.1499_1511del, p.D500Gfs*6).
We did not observe significant differences in the phenotypes of the two alleles. As in affected subject's fibroblasts, Golgi structure was disrupted in mutant cells ( Figure S11 ), but unlike our observations from affected subjects' fibroblasts ( Figure S5 ) and serum/plasma ( Figure S6 ), we found defects in the processing of N-and O-linked glycans (Figure S12A-B ) and decreased glycosphingolipid complexity ( Figure S12C ).
The inner ear was malformed in zebrafish mutants, with abnormally shaped semicircular canals ( Figure 6A-B ). Mechanosensory hair cells in the inner ear ( Figure 6C -D, G) and neuromasts ( Figure 6E -F, H) of mutants had reduced numbers of hair bundles. Response to auditory stimuli was greatly reduced in mutants (2% of 53 mutants responded, compared to 100% of 102 wild types). Homozygous mutant animals were significantly shorter than wild type ones ( Figure 7A Figure 7A-B, F) , slightly smaller eyes ( Figure 7C-D) , and stubby "clubbed" pectoral fins ( Figure 7C-D) . mRNA in situ hybridization showed that cog4 is expressed in these structures (figure S13), and immunohistochemistry showed that the protein is deficient in biallelic mutants ( Figure S14 ). Reduced Alcian blue staining of the jaw in mutants indicated defects in proteoglycan secretion ( Figure 7G-H) , and col1a2 expression was reduced in the fin ( Figure 7I-J) . Expression of collagen type II was normal in the jaw, however, suggesting that not all secreted proteins are affected by biallelic cog4 mutations. Notably, chondrocytes did not stack properly ( Figure 7K-L) . Taken together, these findings establish a role for cog4 in inner ear development and skeletogenesis, associated with defective Golgi structure.
Discussion
We show that a heterozygous de novo p.Gly516Arg COG4 variant is responsible for SWS, a rare skeletal dysplasia characterized by short stature, facial dysmorphisms, hearing loss, cataracts, developmental delay, and normal cognition. This is phenotypically distinct from the three reported individuals with classic, biallelic loss-of-function or hypomorphic COG4 mutations, who presented with seizures, hypotonia, intellectual disability, microcephaly, elevated transaminases and, in one case, recurrent infections, 24, [39] [40] [41] and from individuals with loss-offunction mutations in other COG subunits associated with congenital disorders of glycosylation (CDG). These distinct phenotypes and the recurrent nature of the p.Gly516Arg variant therefore suggest the SWS mutation to be gain-of-function. Supporting this notion, SWS cells have accelerated, rather than the delayed retrograde Golgi-to-ER transport seen in cells with biallelic COG4 deficiency. 24, 40 In addition, loss-of-function COG4-mutant cells have impaired glycosylation and reduced COG4 protein levels, 24 while SWS cells had no reduction in COG4 protein level, with apparently normal glycosylation in serum, plasma and fibroblasts.
In SWS cells, accelerated retrograde transport combines with delayed anterograde transport to disrupt the normal dynamics of Golgi trafficking, creating smaller Golgi volumes. Despite the strikingly abnormal architecture of the Golgi and its collapsed stacks in almost 50% of fibroblasts from individuals with SWS, and the expected maldistribution of proteins toward the ER and away from the Golgi, glycosylation analysis in serum appeared normal, in contrast to the altered serum glycosylation seen in individuals with COG4-CDG. One caveat is that the expression of lobe B subunits was unaltered; prior studies have shown that lobe B is essential for preventing retrograde trafficking of β1,4-galactosyltransferase 1 and α2,6-sialyltransferase 1. 42 Additionally, glycomic analysis of the eleven most abundant fibroblast N-glycans did not detect statistically significant differences between control (n=2) and affected subject (n=5) cells.
However, a comprehensive analysis of processing defects in affected subject cells would require the quantification of a significantly expanded portfolio of N-glycans in order to fully assess precursor/product flux through multiple, specific glycan biosynthetic pathways. The limited glycomic profiles we have quantified in control and affected subject fibroblasts are not sufficient to report whether altered Golgi morphology impacts any particular N-glycan processing pathway. Furthermore, efforts to understand the impact of the SWS COG4 variant on cellular glycosylation may benefit from assessing glycosylation in cell types other than fibroblasts that are more reliant on specific glycosylation pathways.
Decorin is a widely-distributed extracellular matrix proteoglycan containing a single chondroitin sulfate (CS) or dermatan sulfate (DS) chain attached to serine residue 4. 43 We found decorin with a higher molecular weight both in media and inside fibroblasts from affected individuals. This could be due to longer glycosaminoglycan chain length, increased sulfation, or both. In addition, a smaller proportion of decorin is glycosylated with CS or DS. These results indicate that SWS affects at least two different aspects of decorin glycosylation, namely initiation, and polymerization or sulfation. Initiation of proteoglycan glycosylation takes place in early Golgi compartments (cis-and medial-Golgi), while polymerization and sulfation take place in late Golgi compartments (trans-Golgi and trans-Golgi network). 44, 45 This suggests that multiple Golgi compartments are affected in SWS cells. It has been previously shown that the biosynthesis of glycosaminoglycans depends on intact inter-compartmental Golgi transport, 46 and that the COG complex is essential for normal intra-Golgi transport. 24 Our zebrafish data support the fact that COG4 is necessary for normal secretion of proteoglycans ( Figure 7G-H) , and establish that it is required for normal skeletogenesis and cartilage architecture.
Previous reports indicate that both COG4 deficiency and overexpression lead to disrupted vesicular homeostasis. Prior experiments have demonstrated that doubling expression of COG4 protein in control cells via viral transduction led to abnormal retrograde trafficking, 24 and lentiviral complementation of wild-type COG4 in fibroblasts derived from individuals with COG4 deficiency failed to rescue the retrograde trafficking delay. 40 In contrast, overexpression of the wild-type protein rescues the retrograde trafficking delay seen in fibroblasts of affected subjects with deficiencies of COG1, 47 COG5, 34 COG6, 35 COG7, 48 and COG8 22 . Thus, this COG4 dosage effect seems unique among COG complex proteins. A comprehensive investigation of the impact of the SWS mutation on protein level and stability of COG4 and other lobe A subunits is currently being pursued.
One consequence of the recurrent COG4 variant might be the formation of additional protein complexes. Human COG4 is known to interact with syntaxin 5, syntaxin 16, VTI1A, GOSR1, SCFD1, VPS45, RAB1A, RAB4A, RAB30, and VCP. 10 Size distribution studies in affected subject cell extracts showed that COG4 protein was present in high molecular weight complexes, in keeping with the formation of intact COG complexes. Indeed, higher molecular weight complexes appeared to be more frequent in SWS cells, potentially suggesting the recruitment of additional interacting protein(s), which if confirmed may provide a useful avenue for future investigations.
Whatever the cellular perturbations associated with the COG4 p.Gly516Arg variant, they result in the distinctive clinical phenotype of SWS, a skeletal dysplasia (Table 1 ). This is not the first example of a defect in vesicular trafficking altering skeletal homeostasis; other genetic defects cause variable phenotypes such as osteopetrosis 49 with spondyloepimetaphyseal changes and delayed anterograde and retrograde trafficking. 55 To that list, we now add a rare but likely underdiagnosed cause of primordial dwarfism, i.e., Saul-Wilson syndrome.
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